Category

Archives

Bcl-2

BCL-XL antagonism selectively reduces neutrophil life span within inflamed tissues without causing neutropenia

1 views | Jul 29 2021

Emma M Carrington et al. showed a differential survival requirement in activated neutrophils for BCL-XL and revealed a new therapeutic approach to neutrophil-mediated diseases. [Read the Full Post]

Identification of autophagy-related genes as targets for senescence induction using a customizable CRISPR-based suicide switch screen

7 views | Jun 27 2021

Arnout Schepers et al. presented a suicide switch system that allowed genome-wide CRISPR screening in growth-arrested subpopulations by eliminating the proliferating cells during the screen through activation of a suicide switch in proliferating cells. [Read the Full Post]

Structure-Based Design of A-1293102, a Potent and Selective BCL-X L Inhibitor

5 views | Jun 25 2021

Zhi-Fu Tao et al. thought that A-1293102 represented one of the few distinct structural series of selective BCL-XL inhibitors, and thus served as a useful tool for biological studies as well as a lead compound for further optimization. [Read the Full Post]

Immunomodulatory effects of different intravenous immunoglobulin preparations in chronic lymphocytic leukemia

5 views | Jun 24 2021

Ana Colado et al. showed that the IgM/IgA enriched preparation not only affected relevant mechanisms involved in CLL pathogenesis but also had a particular profile of immunomodulatory effects on T cells that deserved further investigation. [Read the Full Post]

Effects of orlistat combined with enzalutamide and castration through inhibition of fatty acid synthase in a PC3 tumor-bearing mouse model

15 views | May 12 2021

Yeu-Sheng Tyan et al. found the synergistic effects of orlistat combined with enzalutamide in vitro and castration in vivo on human prostate cancer. [Read the Full Post]

Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition

11 views | May 05 2021

Bing Z Carter et al. found that co-targeting MCL-1 and BCL-2 improved the efficacy of and overcame preexisting and acquired resistance to BCL-2 inhibition. [Read the Full Post]

Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor

13 views | May 04 2021

Zoltan Szlavik et al. reported the discovery of clinical candidate S64315, a selective small molecule inhibitor of Mcl-1. [Read the Full Post]

Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma

11 views | May 04 2021

Nabanita Mukherjee et al. suggested that several pro-apoptotic BCL2 family members, BCL2-like 11 (apoptosis facilitator) (BIM), phorbol-12-myristate-13-acetate-induced protein 1 (NOXA) or BID, played a role in the combination-induced effects. [Read the Full Post]

Albendazole-Induced SIRT3 Upregulation Protects Human Leukemia K562 Cells from the Cytotoxicity of MCL1 Suppression

25 views | Feb 12 2021

Liang-Jun Wang et al. demonstrated that ABZ-induced SIRT3 upregulation delayed the apoptosis-inducing effect of MCL1 suppression on apoptosis induction in K562 cells. [Read the Full Post]

Kinase activity-independent role of EphA2 in the regulation of M-phase progression

33 views | Jan 04 2021

Yuichiro Kaibori et al. suggested that EphA2 regulated M-phase progression in a manner independent of its kinase activity. [Read the Full Post]